In the 413-patient Phase III OptiTROP-Lung05 study, sacituzumab tirumotecan plus pembrolizumab cut the risk of progression or death by 65% versus pembrolizumab alone in treatment-naïve, locally advanced or metastatic PD-L1-positive NSCLC. In an abstract released ahead of ASCO, median PFS was not reached for the sac-TMT combo versus 5.7 months for Keytruda monotherapy, with ORR of 70.2% versus 42%.

Why It Matters To Oncology

• The readout suggests a TROP2-directed ADC can materially improve first-line outcomes when added to PD-1 blockade in PD-L1-positive advanced NSCLC.

• Investigators said this is the first Phase III study to show a significant PFS benefit for an ADC plus pembrolizumab in this setting.

• OS data are not yet mature, but investigators reported a favorable trend in the sac-TMT arm.

The Financials

• For Merck, the result broadens the potential value of sac-TMT beyond its recent late-stage win in Endometrial Cancer.

• Sac-TMT is being developed under a 2022 collaboration between Merck & Co. and Kelun-Biotech.

• A second pivotal success in a major solid tumor could strengthen the asset's commercial and pipeline importance in ADC drug discovery.

What They're Saying

• "To our knowledge, this is the first Phase III study to demonstrate the significant PFS benefit of an antibody-drug conjugate plus pembrolizumab in the first-line treatment of PD-L1 positive advanced NSCLC compared to pembrolizumab," the abstract authors wrote.

• Safety will remain a key watchpoint: grade 3+ treatment-emergent adverse events of special interest included neutrophil count decrease (17.3%), anemia (9.1%) and stomatitis (5.3%).

What's Next

• Clinicians will look for fuller ASCO data, including hazard ratios, subgroup performance and duration of response.

• OS follow-up will be critical to determine whether the strong PFS and ORR gains translate into a survival benefit.

• Regulatory and guideline implications could follow if the benefit-risk profile holds up in longer follow-up.